Nikolay P Braykov1, Daniel J Morgan2, Marin L Schweizer3, Daniel Z Uslan4, Theodoros Kelesidis4, Scott A Weisenberg5, Birgir Johannsson6, Heather Young7, Joseph Cantey8, Arjun Srinivasan9, Eli Perencevich3, Edward Septimus10, Ramanan Laxminarayan11. 1. Center for Disease Dynamics, Economics and Policy, Washington, DC, USA. 2. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA. 3. Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Center for Comprehensive Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, IA, USA. 4. Infectious Diseases, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. 5. Alta Bates Summit Medical Center, Oakland, CA, USA. 6. Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA. 7. Infectious Diseases, Denver Health Medical Center, Denver, CO, USA. 8. Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. 9. Centers for Disease Control and Prevention, Atlanta, GA, USA. 10. Clinical Services Group, HCA Inc, Nashville, TN, USA; Texas A&M Health Science Center College of Medicine, Houston, TX, USA. 11. Center for Disease Dynamics, Economics and Policy, Washington, DC, USA; Public Health Foundation of India, New Delhi, India; Princeton University, Princeton, NJ, USA. Electronic address: ramanan@cddep.org.
Abstract
BACKGROUND: Modification of empirical antimicrobials when warranted by culture results or clinical signs is recommended to control antimicrobial overuse and resistance. We aimed to assess the frequency with which patients were started on empirical antimicrobials, characteristics of the empirical regimen and the clinical characteristics of patients at the time of starting antimicrobials, patterns of changes to empirical therapy at different timepoints, and modifiable factors associated with changes to the initial empirical regimen in the first 5 days of therapy. METHODS: We did a chart review of adult inpatients receiving one or more antimicrobials in six US hospitals on 4 days during 2009 and 2010. Our primary outcome was the modification of antimicrobial regimen on or before the 5th day of empirical therapy, analysed as a three-category variable. Bivariate analyses were used to establish demographic and clinical variables associated with the outcome. Variables with p values below 0·1 were included in a multivariable generalised linear latent and mixed model with multinomial logit link to adjust for clustering within hospitals and accommodate a non-binary outcome variable. FINDINGS: Across the six study sites, 4119 (60%) of 6812 inpatients received antimicrobials. Of 1200 randomly selected patients with active antimicrobials, 730 (61%) met inclusion criteria. At the start of therapy, 220 (30%) patients were afebrile and had normal white blood cell counts. Appropriate cultures were collected from 432 (59%) patients, and 250 (58%) were negative. By the 5th day of therapy, 12·5% of empirical antimicrobials were escalated, 21·5% were narrowed or discontinued, and 66·4% were unchanged. Narrowing or discontinuation was more likely when cultures were collected at the start of therapy (adjusted OR 1·68, 95% CI 1·05-2·70) and no infection was noted on an initial radiological study (1·76, 1·11-2·79). Escalation was associated with multiple infection sites (2·54, 1·34-4·83) and a positive culture (1·99, 1·20-3·29). INTERPRETATION: Broad-spectrum empirical therapy is common, even when clinical signs of infection are absent. Fewer than one in three inpatients have their regimens narrowed within 5 days of starting empirical antimicrobials. Improved diagnostic methods and continued education are needed to guide discontinuation of antimicrobials. FUNDING: US Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion; Robert Wood Johnson Foundation; US Department of Veterans Administration; US Department of Homeland Security.
BACKGROUND: Modification of empirical antimicrobials when warranted by culture results or clinical signs is recommended to control antimicrobial overuse and resistance. We aimed to assess the frequency with which patients were started on empirical antimicrobials, characteristics of the empirical regimen and the clinical characteristics of patients at the time of starting antimicrobials, patterns of changes to empirical therapy at different timepoints, and modifiable factors associated with changes to the initial empirical regimen in the first 5 days of therapy. METHODS: We did a chart review of adult inpatients receiving one or more antimicrobials in six US hospitals on 4 days during 2009 and 2010. Our primary outcome was the modification of antimicrobial regimen on or before the 5th day of empirical therapy, analysed as a three-category variable. Bivariate analyses were used to establish demographic and clinical variables associated with the outcome. Variables with p values below 0·1 were included in a multivariable generalised linear latent and mixed model with multinomial logit link to adjust for clustering within hospitals and accommodate a non-binary outcome variable. FINDINGS: Across the six study sites, 4119 (60%) of 6812 inpatients received antimicrobials. Of 1200 randomly selected patients with active antimicrobials, 730 (61%) met inclusion criteria. At the start of therapy, 220 (30%) patients were afebrile and had normal white blood cell counts. Appropriate cultures were collected from 432 (59%) patients, and 250 (58%) were negative. By the 5th day of therapy, 12·5% of empirical antimicrobials were escalated, 21·5% were narrowed or discontinued, and 66·4% were unchanged. Narrowing or discontinuation was more likely when cultures were collected at the start of therapy (adjusted OR 1·68, 95% CI 1·05-2·70) and no infection was noted on an initial radiological study (1·76, 1·11-2·79). Escalation was associated with multiple infection sites (2·54, 1·34-4·83) and a positive culture (1·99, 1·20-3·29). INTERPRETATION: Broad-spectrum empirical therapy is common, even when clinical signs of infection are absent. Fewer than one in three inpatients have their regimens narrowed within 5 days of starting empirical antimicrobials. Improved diagnostic methods and continued education are needed to guide discontinuation of antimicrobials. FUNDING: US Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion; Robert Wood Johnson Foundation; US Department of Veterans Administration; US Department of Homeland Security.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Marin H Kollef; Lee E Morrow; Michael S Niederman; Kenneth V Leeper; Antonio Anzueto; Lisa Benz-Scott; Frank J Rodino Journal: Chest Date: 2006-05 Impact factor: 9.410
Authors: Jan J De Waele; Mariska Ravyts; Pieter Depuydt; Stijn I Blot; Johan Decruyenaere; Dirk Vogelaers Journal: J Crit Care Date: 2010-01-15 Impact factor: 3.425
Authors: Eili Y Klein; Elena M Martinez; Larissa May; Mustapha Saheed; Valerie Reyna; David A Broniatowski Journal: J Gen Intern Med Date: 2017-06-20 Impact factor: 5.128
Authors: D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Kruger; K Mayer; M W Pletz; D Storzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-02 Impact factor: 1.041
Authors: Theodoros Kelesidis; Nikolay Braykov; Daniel Z Uslan; Daniel J Morgan; Sumanth Gandra; Birgir Johannsson; Marin L Schweizer; Scott A Weisenberg; Heather Young; Joseph Cantey; Eli Perencevich; Edward Septimus; Arjun Srinivasan; Ramanan Laxminarayan Journal: Infect Control Hosp Epidemiol Date: 2015-10-12 Impact factor: 3.254
Authors: D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Krüger; K Mayer; M W Pletz; D Störzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; Christoph Lichtenstern Journal: Anaesthesist Date: 2017-10 Impact factor: 1.041
Authors: Karl Madaras-Kelly; Makoto Jones; Richard Remington; Christina M Caplinger; Benedikt Huttner; Barbara Jones; Matthew Samore Journal: J Antimicrob Chemother Date: 2015-11-03 Impact factor: 5.790